Baxalta Inc. expanded its hemophilia franchise with FDA approval of Adynovate (antihemophilic factor [recombinant], pegylated) to treat hemophilia A. The therapy, which was built around the company's existing treatment, Advate (octocog alfa, or antihemophilic factor [recombinant]), with pegylation technology from Nektar Therapeutics Inc., extends treatment times to twice-weekly dosing, compared to conventional therapy of three to four doses per week.